The Economic Value of Innovative Treatments over the Product Life Cycle: The Case of Targeted Trastuzumab Therapy for Breast Cancer
- 1 November 2009
- journal article
- Published by Elsevier BV in Value in Health
- Vol. 12 (8), 1118-1123
- https://doi.org/10.1111/j.1524-4733.2009.00572.x
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Cost‐effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2‐positive breast cancerCancer, 2007
- Cost Effectiveness of Adjuvant Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast CancerJournal of Clinical Oncology, 2007
- A Cost-Effectiveness Analysis of Adjuvant Trastuzumab Regimens in Early HER2/neu–Positive Breast CancerJournal of Clinical Oncology, 2007
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerThe New England Journal of Medicine, 2005
- HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness AnalysisJournal of Clinical Oncology, 2004
- New drug development in the United States from 1963 to 1999Clinical Pharmacology & Therapeutics, 2001
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2The New England Journal of Medicine, 2001
- Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.Journal of Clinical Oncology, 1990
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987